Evidence map›Paper›PMID 30818917›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2019

[Real-world study of paritaprevir/ritonavir-ombitasvir combined with dasabuvir for the treatment of chronic hepatitis C 1b genotype infection in China].

Y S Jie, J Yuan, X H Zhang, Y J Guan, Z X Zhao, Y T Chong, L Tao, J P Li, C S Lin

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Y S JieThe Third Affiliated hospital of Sun Yat-sen university, Guangzhou 510630, China.
J YuanThe Third People's Hospital of Shenzhen, Shenzhen 518118, China.
X H ZhangThe Third Affiliated hospital of Sun Yat-sen university, Guangzhou 510630, China.
Y J GuanThe Eighth People's hospital of Guangzhou, Guangzhou 510060, China.
Z X ZhaoThe Third Affiliated hospital of Sun Yat-sen university, Guangzhou 510630, China.
Y T ChongThe Third Affiliated hospital of Sun Yat-sen university, Guangzhou 510630, China.
L TaoThe Third Affiliated hospital of Sun Yat-sen university, Guangzhou 510630, China.
J P LiThe Eighth People's hospital of Guangzhou, Guangzhou 510060, China.
C S LinThe Third Affiliated hospital of Sun Yat-sen university, Guangzhou 510630, China.
Third Affiliated Hospital of Sun Yat-sen University · CNSun Yat-sen University · CN

Funding

Key Projects of Guangdong Science and Technology Plan 2014B020212025
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

2-NaphthylamineAnilidesAntiviral AgentsCarbamatesChinaCyclopropanesDrug Therapy, CombinationGenotypeHepacivirusHepatitis C, ChronicHumansLactams, MacrocyclicMacrocyclic CompoundsProlineRibavirinRitonavir2-NaphthylamineAnilidesAntiviral AgentsCarbamatesCyclopropanesdasabuvirLactams, MacrocyclicMacrocyclic CompoundsombitasvirparitaprevirProlineRibavirinRitonavirSulfonamidesUracilValineDirect-acting antiviral agentHepatitis C, chronicReal-world research

Identifiers

PMID30818917
PMCPMC12768984
OpenAlexW3025575326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.